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Introduction
The gastric cancer (GC) is still the fourth most cancer 
and the second most common cause of cancer-related death 
in the world (Crew et al., 2006; Ferlay et al., 2010; Bray et 
al., 2012). Researchers in public health reported a decline 
in the GC mortality rate was observed during the 26 years, 
however the prognosis for affected patients is still poor 
due to the high aggressiveness of this neoplasm (Silva et 
al., 2011). Even with the advancement of human cancer 
therapy, mechanisms that have advanced in mammals to 
protect cells against cytotoxic drugs in the environment 
will continue to function as an important obstacle to 
successful cancer treatments (Gottesman, 2002; Kim 
and Tononock, 2005; Nobili et al., 2006). A recent 
retrospective analysis showed that adjuvant chemotherapy 
might improve outcomes in patients with potentially 
resectable GC (Zhang et al., 2013). Nevertheless, GC 
cells develop resistance to chemotherapy primarily by 
inactivating apoptotic factors and the effluxing of drugs 
mediated by overexpression of ATP-dependent drug-efflux 
pumps P-glycoprotein (Pgp), more recently known as 
ABCB1 protein (Zhu et al., 2013).
The ABCB1 protein plays an important role in 
the bioavailability of drugs, providing a barrier to the 
entry of xenobiotics, as well as monitoring its output in 
different tissues (Ueda et al. 1986). ABCB1 protein, a 
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 Gastric cancer (GC) is one of the most common malignancies worldwide. The ABCB1 protein, a member of 
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member of the ATP-binding cassette (ABC) transporter 
family, encoded by the ABCB1 gene, and more than 
50 SNPs have been identified in this gene. Furthermore, 
these polymorphisms may have a direct effect on ABCB1 
gene expression and function of the ABCB1 protein 
(Fromm et al., 2002; Ambudkar et al., 2006Salama 
et al, 2006; ; Dean, 2009). Nevertheless, in previous 
studies conducted by our group (Oliveira et al., 2012; 
Wu et al., 2014), described a lack of association of 
the MDR1 C3435T polymorphism with susceptibility 
to GC. Differently, in another field study by Ren et al 
(2012), suggested that the MDR1 gene polymorphism 
was strongly associated with increased susceptibility to 
hepatocellular carcinoma.
In contrast to the extensive knowledge on the 
pharmacological action of ABCB1 protein, this field still 
remains unclear about the correlation between the basic 
clinical- pathological data and ABCB1 protein expression 
status in patients with GC. Besides the prevalence and 
impact on GC patient survival, so it becomes necessary 
to understand the relationship between the expression 
of ABCB1 and impact on survival of patients affected 
by GC. The purpose of this study was to investigate 
the association between ABCB1 immunohistochemical 
expression and overall survival in GC patients, and to 
further to correlation the clinical-pathological data and 
ABCB1 protein expression status in these patients.
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Materials and Methods
We studied the expression of ABCB1 protein in 
patients with GC. Fifty-seven patients diagnosed with GC 
were treated in outpatient Oncology of the Discipline of 
Clinical Gastroenterology of UNIFESP-EPM. Surgical 
specimens was embedded in paraffin and stored in the 
Department of Pathology, UNIFESP-EPM. In this study 
were included patients with gastric adenocarcinoma and 
excluded smaller 18 years age. The study was approved 
by the Ethics Committee of the institution, and all patients 
signed an informed consent form. Data on sex, age, 
diagnosis of GC, histological type, grade of differentiation, 
tumor location, stage, realization of prior chemotherapy 
and survival (date of diagnosis and death) were collected 
from medical record review (paper and electronic).
Immunohistochemistry
Immunostaining was performed on sections of 3 μm 
mounted on 3-aminopropylotrimetoxy-silane (Sigma- 
Aldrich, St. Louis, MO, USA) coated slides. Briefly, 
sections were deparaffinized in xylene, rehydrated through 
graded ethanols, followed by blocking of endogenous 
peroxidase activity in 3% hydrogen peroxide for 20 
minutes at room temperature. Antibody-binding epitopes 
were retrieved by pressure-cooking for 2.5 minutes in 10 
mM sodium citrate buffer (pH 6.0). Sections were then 
incubated with rabbit polyclonal anti-ABCB1 dilution 
1:200 (H-241) obtained from Santa Cruz Biotechnology, 
Inc. (USA), overnight at 4ºC in humid chamber. After 
washing twice with phosphate-buffered saline pH 7.4 
(PBS), slides were incubated with biotinylated second-
stage antibody for 30 minutes, followed by incubation with 
streptavidin-biotin-peroxidase complex (LSAB, Dako, 
Carpinteria, California, USA) for further 30 minutes, at 
room temperature. Staining was carried out using a solution 
3-3’diaminobenzidine tetrahydrocloride (DAB- Dako, 
Carpinteria, California, USA). Washes with PBS were 
performed between each step. The ABCB1 was diluted 
in PBS containing 5% (wt/vol) bovine serum albumin. 
Nuclei were counterstained with Harris hematoxylin 
before mounting slides in Entellan (Sigma-Aldrich, St. 
Louis, MO, USA). Negative and positive controls were 
included in each batch of immunohistochemistry. Section 
of colon cancer known to express high levels of ABCB1 
was included as positive control, while in negative control 
the primary antibody was omitted.
Analysis of immunostaining was performed by two 
investigators. The positive pattern was cytoplasmic 
and was graded semi-quantitatively according to the 
percentage of stained cells and their staining intensity. A 
numerical scoring system with two categories was used to 
assess the observed expression of the proteins. Category 
A documented the number of immunoreactive cells as 0 
or negative (no immunoreactive cells), 1 (<10% 
immunoreactive cells), 2 (10-50% immunoreactive 
cells) and 3 (>50% immunoreactive cells). Category 
B documented the intensity of the immunostaining 
as (negative or no immunoreactive cells), 1 (weak 
immunostaining),  2 (moderate) and 3 (strong 
immunostaining). The values for categories A and B were 
multiplied to give the “immunoreactivity score”, which 
could range from 0 to 9. Zero until 3 were considered 
negative, 4 until 9 were considered positive.
Statistical analysis
The Statistical Package for the Social Sciences v19.0 
was used for statistical analysis. Age was compared 
between groups by the Student’s t-test. The Chi-square test 
was used to determine differences between the two groups. 
Survival was estimated by the Kaplan-Meier method and 
survival curves were compared by the log-rank test.
Results
Expression pattern of the ABCB1 was predominantly 
localized in the cytoplasm, as illustrated in the figures 
below (Figure 1A, 1B, 1C and 1D). There were no 
significant differences between positive expression 
of ABCB1 according to the location of the tumor and 
normal adjacent mucosa (p=0.891) as is demonstrated 
in Table 1. We did not find significant differences when 
we compare the expression of ABCB1 and clinical-
pathological data, as anatomical location (p=1.000), 
stage (I+II vs. III+IV) (p=0.526), Lauren´s classification 
(p=0.763) or histological grades (p=1.000) as showed in 
Table 2. We observed reduced survival of patients with 
GC who were persistently positive for ABCB1 protein 
Figure 1. The Positive Pattern of ABCB1 was 
Predominantly The Cytoplasmic Type. 1.A Normal 
adjacent mucosa to the tumor with negative expression 
of ABCB1, 100X; 1.B Normal adjacent mucosa to the 
tumor with positive expression of ABCB1, 100X; 1.C 
Adenocarcinoma of diffuse type with negative expression 
of ABCB1, 100X; 1.D Adenocarcinoma of intestinal type 
with positive expression of ABCB1, 400X
Table 1. Expression of ABCB1 in The Tumor and 
Normal Adjacent Mucosa to The Tumor
 Positive Negative p
Location n (%) n (%)
Tumour (55) 25 (45.5) 30 (54.5) 0.891
Normal adjacent 22 (46.8) 25 (54.2)
mucosa (47)
Categorical variables are expressed as n (%), #p for Pearson chi-square (x2)
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expression (p=0.030), as plotted in Figure 2. Survival 
analysis of patients with stage III and IV GC showed no 
relationship between the clinical stage and the expression 
of ABCB1 (p=0.125). There was no difference in survival 
of individuals performing chemotherapy, regardless of 
the expression of ABCB1 in normal adjacent mucosa 
(p=0.601) or tumor (p=0.578). Additionally, we observed 
in these patients higher frequency of use of fluorouracil 
(28.9%) followed by folinic acid (26.7%).
Discussion
Most patients in the advanced stages of GC require 
chemotherapy but, one of the greatest obstacles to effective 
chemotherapy is the development of drug resistance. The 
ABCB1 protein is directly related to the control of the 
bioavailability of various substrates actively working 
in both excretion and elimination of drugs and toxic 
substances (Ueda et al., 1986).
In accordance with Baldissera et al (2012) that 
observed increased expression of ABCB1 protein in 
tissues of hepatocellular carcinoma compared to non-
tumor tissues we found higher expression of ABCB1 
protein in GC tissues compared to the normal adjacent 
mucosa. Choi et al (2002) found higher expression of 
ABCB1 protein in moderately differentiated tumors and 
especially in intestinal-type GC of Lauren’s classification. 
Similarly, we found increased expression of ABCB1 
protein in moderately differentiated tumors and intestinal-
type of Lauren. In this study, patients with clinical stage 
III+IV presented higher expression of ABCB1 protein in 
relation to stages I+II.
 Studies show that the level of expression of ABCB1 
protein is related to membrane permeability, intracellular 
drug concentration and drug resistance. The positivity of 
ABCB1 protein between 25% and 71% of GC cells was 
associated with poor prognosis (Lacueva et al., 2000; Xie 
et al., 2004; Wei et al., 2005). Similarly, this study showed 
that patients with GC and ABCB1 protein positive had 
poor prognosis (p=0.03). Although patients with GC have 
been performing chemotherapy ABCB1 protein may cause 
a resistance to treatment. However, (Song et al., 2012) 
supposed that the downregulation of ABCB1 which led 
to intracellular drug accumulation, which led to reduction 
of cell detoxification ability.
One explanation for the lack of association between 
the survival of patients undergoing chemotherapy and 
expression of ABCB1 protein may be because most of our 
patients use drugs that are not known to be substrates for 
ABCB1 protein. Comparing our results with the literature, 
we observed differences in some variables and these can 
be associated with different ethnic groups as well as the 
number of patients included in the study.
In order to confirm all assays that immunohistochemical 
ABCB1 protein expression, we performed several 
analyses to ensure that analytical results were acceptably 
reproducible. Based on these observations, we conclude 
that gastric cancer patients with positive ABCB1 protein 
immunohistochemical expression in the tumor region 
had shorter overall survival. Additionally, we found no 
correlation between the clinical-pathological data and 
ABCB1 protein expression status.
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